Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
Verve Therapeutics Announces 2022 Anticipated Milestones And Preclinical Data On Potential Additional Dosing Regimens For Its Novel Base Editing Programs
Verve Therapeutics, Inc., (NASDAQ:VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today highlighted key milestones anticipated in
Cathie Wood’s ARK Invest Posts Fund Purchases For Monday, Nov. 15, 2021: NTLA, TWOU, VCYT, BEAM, MTLS, PRLB, TSP, ACHR, VLD, SPLK, DIS, BFLY, SGFY, ONEM, ALLO, VERV, QSI, HOOD, DKNG, TWLO, TOST, PAG, GRMN, DDD, MKFG
Intellia Therapeutics (NTLA)
2U (TWOU)
Veracyte (VCYT)
Beam Therapeutics (BEAM)
Materialise (MTLS)
Proto Labs (PRLB)
TuSimple Holdings (TSP)
Archer Aviation (ACHR)
Velo3d (VLD)
Splunk (SPLK)
The Walt Disney
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours.
Verve Therapeutics Q3 EPS $(0.47) Up From $(3.81) YoY
Verve Therapeutics (NASDAQ:VERV) reported quarterly losses of $(0.47) per share. This is a 87.66 percent increase over losses of $(3.81) per share from the same period last year.
Verve Therapeutics Reports Preclinical Data Demonstrating Potent Editing Of ANGPTL3 Gene Using Proprietary GalNAc-LNP Delivery Technology In Non-Human Primates
ANGPTL3 Base Editor Delivered via Internally Developed GalNAc-LNPs Potently Reduced Blood ANGPTL3 Protein by 94-97% in a Novel NHP Model of Homozygous Familial Hypercholesterolemia
GalNAc-LNP Delivery of ANGPTL3 Base
Barron’s Latest Picks And Pans: Alleghany, Blade Air Mobility, Gene Therapy Picks And More
This weekend's Barron's cover story examines the bubbles in cryptocurrency, meme stocks and non-fungible tokens.
Other featured articles discuss the stocks powering 2021's top dividend mutual funds and what comes next now that the pandemic trade is over.
